Juno Therapeutics Inc (NASDAQ:JUNO) – Equities research analysts at FBR & Co decreased their FY2018 earnings per share (EPS) estimates for Juno Therapeutics in a research report issued to clients and investors on Wednesday. FBR & Co analyst E. White now forecasts that the brokerage will earn ($3.48) per share for the year, down from their prior forecast of ($3.28). FBR & Co currently has a “Market Perform” rating and a $30.00 target price on the stock.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. During the same period in the previous year, the business posted ($0.26) earnings per share. Juno Therapeutics’s revenue for the quarter was up 1200.0% on a year-over-year basis. TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Juno Therapeutics Inc (JUNO) Decreased by FBR & Co” was originally published by Daily Political and is the propert of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this piece can be read at http://www.dailypolitical.com/2016/11/29/fy2018-eps-estimates-for-juno-therapeutics-inc-juno-decreased-by-fbr-co.html.

Earnings History and Estimates for Juno Therapeutics (NASDAQ:JUNO)

A number of other brokerages have also commented on JUNO. Vetr lowered shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price objective on the stock. in a research report on Tuesday, August 16th. Standpoint Research assumed coverage on shares of Juno Therapeutics in a research report on Thursday, August 25th. They issued a “buy” rating and a $47.00 price objective on the stock. BTIG Research assumed coverage on shares of Juno Therapeutics in a research report on Tuesday, August 30th. They issued a “sell” rating and a $23.00 price objective on the stock. Maxim Group cut their price objective on shares of Juno Therapeutics from $80.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, August 5th. Finally, Leerink Swann reissued an “outperform” rating and issued a $45.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, September 27th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $40.40.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down 4.48% during mid-day trading on Monday, reaching $21.13. 2,250,119 shares of the company’s stock were exchanged. The stock’s market cap is $2.17 billion. The stock’s 50-day moving average is $27.32 and its 200-day moving average is $32.73. Juno Therapeutics has a 52-week low of $19.41 and a 52-week high of $57.82.

In related news, EVP Robert Azelby sold 12,921 shares of the company’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the transaction, the executive vice president now directly owns 48,640 shares in the company, valued at $1,174,169.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Hans Edgar Bishop sold 23,042 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $30.06, for a total transaction of $692,642.52. Following the completion of the transaction, the chief executive officer now owns 2,541,151 shares in the company, valued at $76,386,999.06. The disclosure for this sale can be found here.

TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Juno Therapeutics Inc (JUNO) Decreased by FBR & Co” was originally published by Daily Political and is the propert of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this piece can be read at http://www.dailypolitical.com/2016/11/29/fy2018-eps-estimates-for-juno-therapeutics-inc-juno-decreased-by-fbr-co.html.

Institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Financial Services Inc. boosted its stake in Juno Therapeutics by 1,433.2% in the third quarter. Rockefeller Financial Services Inc. now owns 3,465 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,239 shares in the last quarter. Advisor Group Inc. boosted its stake in Juno Therapeutics by 51.4% in the third quarter. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,296 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in Juno Therapeutics by 55.0% in the third quarter. Panagora Asset Management Inc. now owns 4,200 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 1,490 shares in the last quarter. Societe Generale purchased a new stake in Juno Therapeutics during the second quarter valued at $153,000. Finally, SG Americas Securities LLC purchased a new stake in Juno Therapeutics during the second quarter valued at $153,000.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.